Want to join the conversation?
Biotechnology company $TMO signed an agreement with $NVS & $PFE to develop & commercialize a next-generation sequencing (NGS) oncology test as a companion diagnostic for non-small cell lung cancer. The NGS-based companion diagnostic test will be developed using $TMO's Ion PGM Dx System and Oncomine assays.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.